Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARDX | 144 | neutral | 2/10 | CEO Michael Raab filed a Form 144 notice to sell 44,500 shares (~$179K at filing) on August 21, 2026, following a patter | Aug 21, 2026 |
| ALLO | 144 | neutral | 2/10 | Douglas Earl Martin, an officer of Allogene Therapeutics, filed a Form 144 notice of intent to sell 29,697 shares of com | Aug 21, 2026 |
| AEON | 3 | neutral | 5/10 | No summary provided | Aug 21, 2026 |
| GILD | CLUSTER | neutral | 3/10 | Three GILD insiders, including the CFO and Chief Communications Officer, sold a total of ~$2.85M in open-market shares o | Aug 21, 2026 |
| QNTM | PRESS-RELEASE | neutral | 2/10 | Quantum BioPharma granted 572,500 stock options to directors, officers, employees, and consultants at C$4.80 per share, | Aug 21, 2026 |
| ARDX | 144 | neutral | 2/10 | Director John E. Bishop filed a Form 144 notice of intent to sell 25,500 shares of Ardelyx common stock, valued at appro | Aug 21, 2026 |
| MANE | CLUSTER | bearish | 5/10 | A significant insider selling cluster at Veradermics (MANE) saw CEO Reid Waldman, CTO Timothy Durso, and two directors s | Aug 21, 2026 |
| APUS | 8-K | neutral | 4/10 | Apimeds Pharmaceuticals US (APUS) entered into an Assignment and Transfer Agreement with FreeT Inc. to acquire certain A | Aug 21, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 240,135 shares to 20 new non-executive employees at an | Aug 21, 2026 |
| VVOS | 8-K | bullish | 5/10 | Vivos Therapeutics announced the grand opening of a new sleep testing and treatment facility in Henderson, Nevada, expec | Aug 21, 2026 |
| TECX | 144 | neutral | 3/10 | Former director Terrance McGuire filed a Form 144 notice to sell 10,200 shares of Tectonic Therapeutic (TECX) valued at | Aug 21, 2026 |
| OMER | CLUSTER | neutral | 2/10 | Two OMER insiders sold a combined $362K in open-market sales over a 7-day window, with Director Thomas Cable selling $27 | Aug 21, 2026 |
| KTTAW | 8-K | bearish | 7/10 | Pasithea Therapeutics received a 180-day extension from Nasdaq, moving the deadline to regain compliance with the $1.00 | Aug 21, 2026 |
| PRTA | INSIDER-BUY | bullish | 4/10 | 10% owner William Scully made a $439K open-market purchase of PRTA shares at $8.79, adding to his position after gifting | Aug 21, 2026 |
| TRIB | F-1/A | bullish | 6/10 | Trinity Biotech filed Post-Effective Amendment No. 2 to its F-1 registration statement, confirming the termination of it | Aug 21, 2026 |
| NEOG | DEFA14A | neutral | 2/10 | Neogen Corporation filed additional definitive proxy soliciting materials (DEFA14A) on August 21, 2026. This follows the | Aug 21, 2026 |
| GRML | PRESS-RELEASE | bullish | 6/10 | Greenland Mines Ltd received Greenland government approval to transfer a key mineral exploration license for the Sarfart | Aug 21, 2026 |
| ALVO | 6-K | bullish | 7/10 | Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for AVT34 (proposed durvalumab | Aug 21, 2026 |
| HOWL | 425 | bullish | 7/10 | Werewolf Therapeutics (HOWL) filed a Form 8-K (filed as a 425 communication) confirming the definitive merger agreement | Aug 21, 2026 |
| HOWL | 8-K | bullish | 7/10 | Werewolf Therapeutics (HOWL) entered into a definitive merger agreement to be acquired by Ambros Therapeutics in a rever | Aug 21, 2026 |
| SNYR | 8-K | bearish | 7/10 | Synergy CHC Corp. received a Nasdaq notice on August 20, 2026, for failing to timely file its Q2 2026 Form 10-Q (Listing | Aug 21, 2026 |
| AZTR | 8-K | bullish | 5/10 | Azitra (AZTR) announced it has regained compliance with NYSE American continued listing standards, resolving previously | Aug 21, 2026 |
| LFVN | PRESS-RELEASE | neutral | 2/10 | LifeVantage declared a quarterly cash dividend of $0.050 per share, payable September 15, 2026 to holders of record Sept | Aug 21, 2026 |
| ABUS | 8-K | bullish | 7/10 | Arbutus Biopharma announced plans to launch a modified Dutch auction tender offer to repurchase up to $230 million of it | Aug 21, 2026 |
| SNYR | PRESS-RELEASE | bearish | 8/10 | Synergy CHC Corp. (SNYR) disclosed a Nasdaq non-compliance notice for late filing of its Q2 2026 Form 10-Q. The company | Aug 21, 2026 |
| HOWL | PRESS-RELEASE | bearish | 7/10 | Werewolf Therapeutics (HOWL) announced a definitive all-stock merger with Ambros Therapeutics, valuing Ambros at $500M a | Aug 21, 2026 |
| MIST | PRESS-RELEASE | bullish | 7/10 | Milestone Pharmaceuticals announced first patient enrollment in the Phase 3 ReVeRA-301 pivotal trial evaluating etripami | Aug 21, 2026 |
| GOSS | 8-K | bearish | 6/10 | Gossamer Bio entered into a securities purchase agreement for a two-tranche private placement of pre-funded warrants and | Aug 21, 2026 |
| TBPH | DEFM14A | bullish | 7/10 | Theravance Biopharma (TBPH) is being acquired by Zymeworks (ZYME) for $17.00 per share in cash plus one CVR per share, w | Aug 21, 2026 |
| NSRX | EFFECT | neutral | 5/10 | Nasus Pharma's F-1 registration statement (File No. 333-293950) was declared effective by the SEC on August 20, 2026, en | Aug 21, 2026 |